Skip to main content

Table 1 Baseline characteristics of patients initiating urate-lowering therapy

From: Adherence with urate-lowering therapies for the treatment of gout

Characteristic Total population (N = 4,166)
Mean age, years (SD) 62 (14)
Gender, N (% male) 3,113 (75)
Number of provider visits for gout prior to ULD initiation, mean (SD)* 1.67 (1.62)
Number of physician visits for any diagnosis prior to ULD initiation, mean (SD)* 6.16 (5.81)
Hospitalization, N (%)* 782 (19)
Number of provider visits for gout after ULD initiation, mean (SD)† 1.73 (2.43)
Charlson comorbidity score, mean (SD) 1.06 (1.64)
Associated comorbidities, N (%):  
   Hypertension 2,904 (70)
   Dyslipidemia 1,976 (47)
   Coronary heart disease 1004 (24)
   Diabetes mellitus 989 (24)
   Renal insufficiency 816 (20)
   Renal failure 629 (15)
   Peripheral arterial disease 243 (6)
   Nephrolithiasis 196 (5)
Medications associated with gout or difficulty treating gout, N (%):  
   Thiazide diuretics 1,569 (38)
   All diuretics 2,259 (54)
  1. *Over the 12 months prior to initiation of a ULD; †over the 12 months after initiation of a ULD.
  2. SD, standard deviation; ULD, urate-lowering drug.